Waldenström with clinical / biochemical features concerning for transformation to DLBCL:...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-WM-TRANSFORMATION-PROGRESSION`
Type	Red flag
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-WM`
Sources	`SRC-ESMO-WM-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	Waldenström with clinical / biochemical features concerning for transformation to DLBCL: rapid LDH rise, asymmetric / rapidly enlarging nodal or extranodal mass, PET-CT SUVmax >10 (WM rarely PET-avid; high SUV concerning), B-symptoms in previously asymptomatic patient, or hypercalcemia. Mandates urgent excisional biopsy of PET-avid lesion.
Clinical direction	intensify
Category	transformation-progression

Trigger Logic

{
  "any_of": [
    {
      "finding": "ldh_doubled_in_weeks",
      "value": true
    },
    {
      "finding": "rapid_progression",
      "value": true
    },
    {
      "comparator": ">",
      "finding": "pet_suvmax",
      "threshold": 10
    },
    {
      "finding": "wm_richter_like_transformation_suspect",
      "value": true
    },
    {
      "finding": "biopsy_shows_dlbcl",
      "value": true
    },
    {
      "finding": "new_b_symptoms",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Notes

Histologic transformation to DLBCL occurs in 2-10% WM lifetime (lower than CLL Richter). Once confirmed by biopsy, treat as de novo DLBCL with R-CHOP (with HBV / IgM-flare considerations); MYD88 status of the transformed clone informs prognosis but not initial therapy. Distinct from "IgM flare" — transient IgM rise after rituximab — which is not transformation and resolves spontaneously. PET-CT in baseline WM (rarely indicated for staging) becomes essential when transformation suspected — high SUVmax in single asymmetric lesion mandates excisional biopsy of that lesion (core may miss focal transformation).

Used By

Algorithms

ALGO-WM-2L - ALGO-WM-2L